DCF advises Advanced Pharma on its sale to Avella Specialty Pharmacy – Press release | Deloitte US has been added to your bookmarks.
Deloitte Corporate Finance LLC advises Advanced Pharma on its sale to Avella Specialty Pharmacy
CHARLOTTE, N.C., Feb. 02, 2017 — Deloitte Corporate Finance LLC acted as financial advisor to Houston-based Advanced Pharma, Inc. (Advanced Pharma) on its sale to Avella Specialty Pharmacy (Avella). Advanced Pharma is an FDA-registered 503B Outsourcing Facility providing compounded products to hospitals, health systems and ambulatory surgery centers nationwide. The transaction closed Dec. 1, 2016.
Advanced Pharma maintains a state-of-the-art, 35,000-square-foot production facility with rigorous quality controls. Advanced Pharma’s extensive product portfolio, differentiated production capabilities and stringent compliance standards have enabled it to meet the growing demand for customized pharmaceuticals across the U.S. The transaction will support Advanced Pharma’s continued national growth and expansion into new therapeutic classes.
“We could not be more pleased by the outcome of this transaction. Avella is an excellent partner with extensive resources and expertise that we can leverage to continue our growth trajectory,” said Bourjois Abboud, founder and CEO of Advanced Pharma, Inc. “Deloitte Corporate Finance was instrumental in guiding us through all aspects of the process and helping us position the company for an optimal outcome.”
“Advanced Pharma has established a reputation for quality and excellence and we were excited to advise them through this process,” said Jason Porter, senior vice president, Deloitte Corporate Finance LLC. “Our team is looking forward to seeing the combined capabilities of an Advanced Pharma – Avella partnership and the creation of a leading national provider of compounded sterile preparations.”
About Advanced Pharma, Inc.
Advanced Pharma is a leading provider of sterile compounded preparations used in the acute care setting. This Texas-based compounding facility is dedicated to maintaining the highest levels of quality in all of its preparations. It is an FDA-registered 503B Outsourcing Facility, meeting FDA guidelines for sterility and safety including the maintenance of current Good Manufacturing Practices within the company’s facilities. Advanced Pharma offers compounded formulations across 14 therapeutic classes within its 35,000-square-foot production facility. These preparations are administered by injection, IV or pump in the hospital setting and include pain management medications as well as therapies for dehydration, infection and other serious medical issues. For more information, visit http://www.advancedpharma.net/.
About Avella Specialty Pharmacy
Headquartered in Phoenix, Arizona, Avella is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. In 2016, Avella was named Specialty Pharmacy of the Year by NASP, a nationally recognized pharmacy trade committee. Inc. Magazine’s 2016 list of the 5,000 fastest-growing private companies in the country included Avella for the tenth consecutive year and also recognized Avella as the fastest-growing woman-led company in 2015. In addition, the Arizona Corporate Excellence Awards named Avella Specialty Pharmacy as the second fastest-growing private company based in the state in 2015. For more information, please visit www.avella.com.
About Deloitte Corporate Finance LLC
Deloitte Corporate Finance LLC provides strategic advisory services and M&A advice that help corporate, entrepreneurial, and private equity clients create and act upon opportunities for liquidity, growth and long-term advantage. With an in-depth understanding of the marketplace and access to a global network of investment bankers, we help clients confidently pursue strategic transactions in both domestic and global markets. Deloitte Corporate Finance, together with the Corporate Finance Advisory practices within the Deloitte Touche Tohmatsu Limited network of member firms, include in excess of 1,900 professionals, who work collaboratively across 150 international locations. With our significant experience providing investment banking services across key industries, we are able to offer our clients solutions that help them to achieve their strategic objectives. For more information, visit www.investmentbanking.deloitte.com.
Prior engagement performance is no guarantee of future performance and may not be representative of the experience of other clients. This communication is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security.
Deloitte Corporate Finance LLC, an SEC registered broker-dealer and member of FINRA and SIPC, is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking products and services within the United States are offered exclusively through Deloitte Corporate Finance LLC. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.